Use of the Gore Tigris Vascular Stent in Advanced Femoropopliteal Peripheral Arterial Disease
| Autor: | Giulia Guaccio, Stefano Bascetta, Giulio Tommasino, Pierleone Lucatelli, Carmelo Ricci, Antonio Benvenuti, Marco Cini, Eugenio Neri |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Male
medicine.medical_specialty medicine.medical_treatment Femoral artery 030204 cardiovascular system & hematology 030218 nuclear medicine & medical imaging Lesion 03 medical and health sciences Peripheral Arterial Disease Aged Female Humans Prospective Studies Treatment Outcome Ultrasonography Doppler Femoral Artery Popliteal Artery Stents 0302 clinical medicine Restenosis medicine.artery medicine Radiology Nuclear Medicine and imaging Stage (cooking) Prospective cohort study Ultrasonography business.industry Doppler Stent medicine.disease Popliteal artery Surgery medicine.symptom Cardiology and Cardiovascular Medicine business Calcification |
| Zdroj: | Journal of vascular and interventional radiology : JVIR. 29(5) |
| ISSN: | 1535-7732 |
| Popis: | Purpose To prospectively evaluate the safety and efficacy of using the Tigris vascular stent (Gore, Flagstaff, Arizona) alone or in combination with the Viabahn stent (Gore) for revascularizing femoropopliteal Trans-Atlantic Intersociety Consensus (TASC) type B–D lesions with varying degrees of calcification. Materials and Methods Patients with Rutherford stage ≥ 3 and TASC type ≥ B were included in the study. From January 2015 to April 2017, 31 segments in 31 patients (21 men, ovarall mean age 73.3 ± 9.2 years) were treated. The breakdown by TASC type and Rutherford stage were TASC B (n = 12), C (n = 6), and D (n = 13), and Rutherford 3 (n = 28) and 4 (n = 3). The lesions were located in the common femoral artery (n = 1), superficial femoral artery (SFA; n = 20), distal SFA to P1 (n = 3), popliteal P1 (n = 1), popliteal P1–3 (n = 3), popliteal P2–3 (n = 2), and 1 femoropopliteal bypass. There were 18 occlusions (58.1%) and 13 stenoses (41.9%). The mean diseased segment length was 15.5 ± 9.9 cm with 80.6% of moderate/severe calcification. The follow-up consisted of color Doppler ultrasound and clinical assessment at 1, 3, 6, 9, 12, and 15 months. Results Technical success was 100%. There were no periprocedural or postprocedural complications. The mean stented lesion length was 17.2 ± 10.5 cm with a mean follow-up of 13.1 ± 6.9 months. Primary patency rates at 6, 9, 12, and 15 months were, respectively, 100% (24/31 patients), 90.5% (21/31 patients), 88.9% (20/31 patients), and 80% (15/31 patients). The median postprocedural Rutherford stage was 1. Three occlusions occurred at 7, 9, and 14 months, leading to a target lesion revascularization of 9.7% and a secondary patency of 100% at 15 months. Logistic analysis results demonstrated that lesion length ( P = .003) was associated with reocclusion. Amputation-free survival at 15 months was 100%. Intrastent restenosis was observed in four cases (12.9%) but none were associated with worsening of symptoms. No stent fractures were observed. Conclusions The Tigris stent used alone or in combination with a Viabahn stent for femoropopliteal TASC B–D lesions demonstrated acceptable 12-month primary patency with a low reintervention rate. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|